Short answer
Jade Biosciences, Inc. (JBIO) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$56M
- +17.7% YoY · −38.1% QoQ
- EPS (diluted)
- −$0.76
- +77.4% YoY · −33.3% QoQ
Source: XBRL data from the Jade Biosciences, Inc. (JBIO) Q2 2026 10-Q on SEC EDGAR. USD.
Jade Biosciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes stated in provided Risk Factors section relative to the 2025 10-K
- Liquidity risk: $461.2 million in cash, cash equivalents, and investments expected to fund operations for at least twelve months
- Clinical-development risk: $86.1 million research and development expense through June 30, 2026
- Operating-loss risk: $96.1 million net loss and $67.7 million operating cash outflow in six months
- Investment risk: $353.955 million marketable securities with $568 thousand unrealized losses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Jade Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.